First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
Rodrigo Dienstmann, Ulrik Lassen, Jonathan Cebon, Jayesh Desai, Michael P Brown, Stefan Evers, Fei Su, Weijiang Zhang, Frederic Boisserie, Brian Lestini, Kathleen Schostack, Valerie Meresse, Josep Tabernero
Targeted Oncology | SPRINGER | Published : 2016
This study was funded by Hoffmann-La Roche, which provided institutional research support to UL, JD, MPB and JT. RD and JC have no conflicts of interest to declare. SE, FS, WZ, FB, BL, and KS, and VM are employees of Hoffmann-La Roche. SE, WZ, FB, BL, and KS hold stock of Hoffman-La Roche as an employment benefit.